Zoetis (Zoetis) Debt-to-Equity

: 1.35 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Zoetis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3 Mil. Zoetis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6,752 Mil. Zoetis's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4,997 Mil. Zoetis's debt to equity for the quarter that ended in Dec. 2023 was 1.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zoetis's Debt-to-Equity or its related term are showing as below:

ZTS' s Debt-to-Equity Range Over the Past 10 Years
Min: 1.35 Med: 2.61 Max: 4.56
Current: 1.35

During the past 13 years, the highest Debt-to-Equity Ratio of Zoetis was 4.56. The lowest was 1.35. And the median was 2.61.

ZTS's Debt-to-Equity is ranked worse than
91.81% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs ZTS: 1.35

Zoetis Debt-to-Equity Historical Data

The historical data trend for Zoetis's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

2.44

1.95

1.48

1.84

1.35

Zoetis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																1.84	1.50	1.46	1.33	1.35

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zoetis Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zoetis's Debt-to-Equity falls into.

Zoetis Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zoetis's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3	+	6752)	/	4997
	=	1.35

Zoetis's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3	+	6752)	/	4997
	=	1.35

Zoetis (NYSE:ZTS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zoetis Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zoetis's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zoetis (Zoetis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ZTS:Mexico 1ZTS:Italy ZOE:Germany ZOE:Germany ZOE:Germany Z1TS34:Brazil

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Executives

Roxanne Lagano	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst	director	ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed	director	C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki	officer: Executive Vice President	C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David	officer: SVP and Acting CFO	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran	officer: Executive Vice President	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp	officer: Executive Vice President	C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden	director	16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005